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Historically, the advancements made by the hormonal contraceptive industry have been 
astronomical. Scientists were able to formulate a medication that would mimic a women’s 
natural hormones in order to suppress ovulation. By way of this invention, women have finally 
been given a method to independently control their bodies the way they see fit. While the 
benefits of hormonal contraceptives consist of autonomy, among many other non-contraceptive 
reasons, the side effects have prompted further examination of this drug. It has been discovered 
that this pro-woman drug came with its risks. Common complaints about depressive moods have 
begun to be noted and associated with these drugs. 
Currently in practice, a patient may enter the clinic and request the initiation of hormonal 
therapy. Depending on the age, clinicians would normally recommend forms such as the oral pill 
or even Depo-Provera shot or an intrauterine device (IUD) as they would require less effort from 
the patient to maintain. While those methods may work well for some, it may not work for 
everyone. Without closely looking into each patient’s psychological history and predisposing 
factors prior to choosing a contraceptive, the wrong form without close monitoring could lead to 
less than ideal outcomes. In order to avoid these potential life altering affects, implementing 
closer patient monitoring in the clinics is recommended.  
This paper discusses the current clinical issue pertaining to the association between 
hormonal contraceptive (HC) use in women and depression. The PICOT question that stands to 
be evaluated in this paper is: In women currently taking hormonal contraceptives (P) how does 
individualized monitoring (I) compared to no monitoring (C) decrease the risk of hormonal 
contraceptive non-compliance related to depressive symptoms (O) over a 3-month period (T)? 
Upon drafting this topic, prior recommendations were made by the university’s faculty, such as 
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feasibility of obtaining the necessary information, and how it could improve practice, which have 
been taken into consideration and altered.  
Implementation and Benchmark Project 
 
Rationale for the Project 
Currently in the United States, depression is arguably one of the most controversial health 
issues to date. Depression, also known as major depressive disorder (MDD) or clinical 
depression has been identified as the fourth leading condition related to disability worldwide 
(Blanco et al., 2010). Seeking changes in current practice to reduce the negative outcomes of HC 
us has shown to be a crucial aspect in providing safe and effective care to patients.  
Since its launch in the 1960’s, HC remains one of the first treatments of choice for 
pregnancy prevention and hormone therapy. The medication presents in various forms, such as 
oral pills, intrauterine devices, and vaginal rings to name a few. HCs contain either a 
combination of progestin and estrogen, or progestin only. The wide variety HC methods help to 
accommodate numerous women with their lifestyle and health needs. For many, their HC use is 
just one facet of treatment used to balance hormones, as well as reducing the effects of 
gynecological disorders. The clinical issue nurse practitioners face with prescribing HC’s, are its 
risks and benefits. HC over the years has received negative reviews, as it has been related to 
predisposing factors women may have that places them at an increased risk for side effects 
during use. Side effects including, but not limited to, weight gain, headaches and mood swings, 
are all possible contributing factors to depression in women. Given the extensive studies behind 
the benefits of HC use, it has become a top of choice for women. However, its link to potential 
adverse effects on a woman’s psychological wellbeing is still in question. These effects then lead 
to lack of adherence to their regimen. Adequate monitoring of women on these contraceptive 
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drugs, notably in the first six months of use is vital. As the effectiveness of hormonal 
contraceptive monitoring is assessed, changes to current practice can be adjusted in order to 
provide safer and more efficient care to patients.  
The aim of this paper is to cultivate a plan for change in clinical practice on the use of 
HC monitoring in decreasing the psychological mood effects to improve adherence. The 
synthesis of this nursing research is designed in such a way that it evaluates the PICOT question 
at hand. A conclusion to the 3-month project will provide results as to whether this change 
should be implemented continuously. The findings of this paper can then be integrated into the 
professional setting to help in improving the quality of health care.  
Literature Synthesis. 
While inquiring about the relationship between hormonal contraception use and 
depression, the use of specific keywords were used in order to condense the search results of 
peer reviewed articles through online databases such as, CINAHL Complete and Academic 
Search Complete. The databases were searched using the keywords: hormonal contraception, 
birth control, major depressive disorder, depression, weight gain, and risk factor. The searches of 
databases were further condensed to those published between the years of 2013-2020 and written 
by nurses and medical providers. The search was further adjusted as needed to include similar 
key terms to advance the search for relevant evidence. The articles selected for this literature 
review were heterogeneous, ranging from systematic to literature reviews. It was observed that 
out of the 12 articles analyzed, common results were concluded. A further review of each study 
follows. 
During 2013-2016, 8.1% of American adults aged 20 and over experienced depression in 
a given 2-week period. Prevalence estimates that women (10.4%) were nearly twice as likely to 
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have depression than men (5.5%) (Brody et al., 2018). Unfortunately, these prevalence estimates 
provided do not differentiate between populations that are considered at higher risk, such as 
women taking hormonal contraception. It has been estimated that among the women selected to 
represent that majority of women, roughly 82% of women currently use or have used HC during 
their reproductive years (Cheslack-Postava et al., 2014). Given that percentage, lifetime 
prevalence estimates are about 36.8% for the development of psychological disorders for 
women.  
Several studies have determined a correlation between HC use and first prescription and 
diagnosis of depression in women (Yonkers et al., 2017). Researchers of the Danish Sex 
Hormone Registry Study looked at young women ages 15-34 over the course of 13 years. They 
noted that out of those women, 55.5% were current or resent users of HC. From the overall study 
population of over a million, more than 133,000 first prescriptions for anti-depressants were 
prescribed. In addition, McCall et al. (2017) found that more than 23,000 women who received 
their first diagnosis of depression. The incidence rates of first use of antidepressants and first 
diagnosis of depression were 2.2 per 100 person-years and 0.3 per 100 person-years, 
respectively, among users of hormonal contraceptives (McCall et al., 2017). This finding bolsters 
the concern that the negative outcomes on psychological mood with HC use has a causative link 
to the onset of side effects over the course of a woman’s adulthood.  
Most notably, depression rates in adults have been linked to long-term use beginning in 
teenage years. A study of 1,236-woman ages 20-39 reported 16% of the study group who began 
HC during their teenage years met the criteria for depression. Whereas only 9% of women who 
began HC in their adult years met the criteria for depression. Suggesting that the use of HC can 
have long standing psychological affects later in life if initiated during early reproductive years.  
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Absolute risk of depression has been determined to vary among women using certain forms of 
hormonal contraception. Prior studies conducted by scholars suggest the link between HC and 
the development of depression is low in otherwise healthy women (Begsdotter et al., 2017).  
However, HC’s such as the pill, carry higher risks than its’ counterparts, as it increases a 
woman’s risk of depression by up to 80% when compared to nonusers (Zettermark et al., 2018). 
Of note, reports of safety among intrauterine devices (IUD) are being concluded, when compared 
to other forms of birth control that relasease synthetic forms of hormones. IUD’s deliver no form 
of hormones and are an effective and reversible form of contraception and remain good options 
for women who seek pregnancy prevention without the potential mood side effects (Ouyang et 
al., 2019).   
Influences of HC use has since been related to increased psychological side effects, 
which continue to be one of the contributing factors of non-compliance towards their HC 
regimen (Schaffir et al., 2016). In women who’s aim is to prevent pregnancy or alleviate 
unfavorable menstrual symptoms, discontinuation of these medications pose more threat.  
Schaffir et al. (2016) noted that the main cause of non-compliance with medication is the side 
effects. Studies show that it take one to three months for a woman’s body to become acustom to 
HC use. It is at this time where many side effects such as acne, bleeding irrgularites, and also 
some prementrural symtpmtoms level out. However, depressive mood side effects have been 
shown to peak after the first six months of use. While the relative risk for complications are low, 
adjustments or avoidance of certain hormonal contraceptive should be adopted by clinicians for 
women who report signs of mood changes. When paired with this information, it would be 
beneficial for healthcare practitioners to incorporate the use of HC patient monitoring to seek out 
further evidence and expand knowledge of such issues. Taking note of this trend will allow 
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practitioners to continuously implement the monitoring protocol and change behaviors to 
promote compliance, as well as highlight the alternative hormonal contraceptive options that 
may be deemed effective for women with various ailments (Phiri et al., 2015). 
Considering the aspects that promote depression, one article focuses on women’s 
perceived body image while on HC. It mentioned that during the course of therapy, there were 
participants that removed themselves from taking the HC due to negative perceived body image 
from the HC. The article affirms the notion that HC increases the risk for psychological effects, 
as the medication was proven to cause weight gain as well as breast tenderness and abnormal 
peripheral edema, thus promoting depressive symptoms (Morotti et al., 2017). For some women, 
their perception of body image is trivial compared to the potential outcomes of not being on HC.  
While, for others the change can bring forth negative feelings towards it, leading to affected 
mood and cessation of the treatment.  
In clinical practice, practitioners understand that adequate monitoring for women taking 
hormonal contraceptive and health risks is required. Making use of the self-report questionnaires 
made available such as, Clinically Useful Depression Outcome Scale (CUDOS-D) is beneficial 
for risk monitoring. CUDOS-D has proven to be a reliable measurement of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5) definition of clinical depression. A psychiatric 
clinic conducted a study of 1,115 clinically depressed patients, who were given CUDOS-D 
questionnaire as part of their initial and subsequent treatments. Of the participants, 98% reported 
that the CUDOS-D questionnaire took less than 3-minutes to complete, as well as 40% who 
expressed their preference to integrate CUDOS-D into their visits to better monitor their 
treatments (Zimmerman et al., 2018). The patients depend on the counseling, care and proper 
disclosure provided by the practitioners throughout their treatment as well as effectiveness in 
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alleviating possible side effects. Utilizing the detailed history to create a personalized treatment 
plan along with advising patients on the various contraceptive forms, providers are able to help 
patients judge the level of risk for exhibiting potential side effects (Ryan et al., 2014). This will 
allow the patient to take control of their care alongside the counseling of a licensed practitioner, 
which may result in increased adherence to treatment, as well as lower psychological effects. 
Project Stakeholders 
Our patients who range from childbearing, to menopausal ages are the most important 
stakeholders for this project. Also, those impacted by this project include but not limited to the 
owners of the North Dallas Women’s Clinic, the healthcare providers, such as the nurse 
practitioners, medical assistants, and pharmaceutical contracts in which the clinic is affiliated 
with. Depression affects not only the patient, but those around them as well, including their 
families and those around them in various ways. The healthcare providers in this project are 
collaborating to implement a new protocol to efficiently monitor the patient while on their HC 
regimen 
It is important to understand the possible implications of HC and monitor how it can 
positively or negatively affect those involved. “Integrating the expertise of the stakeholders in 
the implementation of this project is useful in strengthening the project by forming academic 
partnerships in order for the constant exchange of knowledge and methods to promote patient 
safety and wellbeing.” (Melnyk & Fineout-Overholt, 2019, p. 274). A lot is at stake when 
implementing a new project into practice. However, with careful planning and consideration for 
all those who will potentially be affected will help in the planning and follow-through of this 
change. 
Implementation Plan 
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The location for the change project will take place at North Dallas Women’s Clinic, 
where the practitioners see various patients from adolescents to adulthood. At this clinic, women 
receive family planning services as well as prescriptions for hormonal contraceptives and 
referrals to specialized women centers. In order to determine cause for change, data regarding the 
occurrence of HC cessation and non-adherence, as well as pre-existing reports of mood changes 
in selected study group are needed. Although specific training is not necessary, each role has a 
potential impact on the implementation of this project. By utilizing the knowledge of the nurse 
practitioner and their vast knowledge of women’s health, along with the knowledge of the 
different forms of HC provided by the pharmaceutical department, optimizing patient care is 
made possible through the integration of each interpersonal role.  
 Permission from the facility itself is needed to conduct this project, as well as from the 
selected patients. Fortunately, many resources are available to aid this project, as this project has 
access to nearby allies in the pertaining field. Barriers exist in the efforts to implement this 
project. Compliance from healthcare providers to accept and adapt to the change in practice is 
one step. Adding on additional steps to their routine at may come as an inconvience, but with 
continued practice and reinforcement full adjustment is expected. To minimize these barriers, a 
set schedule/plan for implantation will be created and given to those involved in the project.  
Reminders will also be sent out to complete the necessary tasks. In order to find applicable 
patients and enact the project, there is a potential need to access the electronic health record 
(EHR). Suitble patients include those who are scheduled to begin a HC treatment withing the 
next two- weeks or those who have began a treatment in the past two- weeks. Prior the start of 
the project, flyers will be made and placed on bulletin boards for patients to view and seek 
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involvement if interested. This recruitment method will also bring in needed new patients to the 
clinic. 
During the three-month course of the project, the graduate student as well as the 
healthcare provider will evaluate the course of the HC regimen and conduct personalized 
monitoring of each patient. Implementing the monitoring will include determining women who 
are within the first month of beginning a HC regimen. Upon approval of participation, an initial 
survey will be conducted on day one to determine their choice of HC, perceptions of the 
medication, and potential pre-existing reports of depression to create a baseline. Thereafter, a 
survey will be sent out electronically via the patients preferred method of communication (i.e. 
phone call, text, or email) every three- weeks for three-months. Special attention must be paid to 
identify patients whose scores are increasing. Providers will then take a closer look at the patient 
to identify any contributing factors. The goal of a long-term implementation of this change is to 
show a decrease in CUDOS-D scores during the course of treatment, if previously higher. At the 
end, the patient will be scheduled for a final follow-up appointment ninety days after continuous 
use of the HC. An assessment for any changes to their psychological wellbeing will then be 
compared to their baseline. By implementing this project, we expect to help provide the patient 
with sufficient education and possible safer alternatives based on their needs. 
Timetable/Flowchart 
 Implementation of the patient monitoring project will begin with the start of the semester. 
On August 31st, 2020, a meeting with the clinic office manager, Dr. Machupali, Ms. Anush, 
WHNP, in order to deliver project proposal, and identify potential patients who will be reached 
to join this study. Once approved, a clear outline and purpose for this change will be outlined and 
given during a presentation to the office staff- billing manager, business manager, referral 
CONTRACEPTIVE MONITORING                                                                                            13 
 
 
coordinator, schedulers, and the medical assistant team lead on September 1st. During this 
presentation, any questions or suggestions to better tailor this change to better align with the 
clinics processes will be answered and considered. A week will be taken in order to reach out 
and receive acceptance from at least 10 patients, as well as apply any minimal changes to the 
project. On Monday, September 7th formal training will begin. The MD, and WHNP will receive 
training first, as they are the forefront of this project. Here a discussion about the clinics specific 
or general provider protocol for hormonal contraceptive initiation. Next, training with the 
medical assistants, which is split into 15-30-minute sessions, will begin and take place for two 
days. Their understanding of the CUDOS-D questionnaire and interview process for patients 
undergoing HC is crucial to the success of this project as they will be the ones delivering these to 
the patients during the initial and follow-up visits. Training will end September 10th so that a 
mock trial can take place Friday, September 11th to confirm understanding. Monday, September 
14th will be the official start of the implementation which will commence on for until November 
30th. 
Data Collection Methods 
 Upon completion, evaluation of the benefits of hormonal contraceptive monitoring will 
be based on the patients’ reports of symptoms suggesting depression using the Clinically Useful 
Depression Outcome Scale (CUDOS-D), as this scale can be used without extra costs for the 
purpose of this project. The checklist of points the providers should hit such as, asking the 
patient how their course of HC treatment is going. Do they notice any side effects? If so describe 
them, as well as asking about their adherence to the medication- have they missed a dose? Are 
they considering a new form or method? These questions will help assess the success of this 
project.  In order to determine the impact of this project against the women’s health clinic, an 
CONTRACEPTIVE MONITORING                                                                                            14 
 
 
additional short patient satisfaction survey will be sent out regarding patient’s overall approval 
with the new implemented monitoring. From there. access to new enrollment and retention of 
patients will be assessed.  
Cost/Benefit Discussion 
 With any implementation of change, there is some cost associated with the initial startup. 
Funding will be needing in order to cover the costs of training, which will be applied to the 
staff’s education hours. An estimated one to two educational hours will be allocated to each staff 
member in order to cover the training days. On average, the six staff members that comprise the 
medical assistants, scheduler, and referral coordinator make an estimated $11-20 per hour, which 
will cost the clinic $22-40 per employee. A maximum of $300 will be needed to cover the costs 
of training. The remainder costs associated with this three-month project is minimal. The 
CUDOS-D form is readily available via the internet. Purchases are small and only require paper 
and printouts for flyers, costing $25 for paper and ink. The participants do not need to make 
frequent visits as monitoring will be done offsite. Overtime, the cost analysis of implementing 
this project should be beneficial for both the clinic and the patients, as positive outcomes can 
bring in more patients from referrals. This project allows for guaranteed better care that is 
patient-centered, more reliable and lastly safe, which in return grants fewer out-of-pocket 
expenses and visits in regard to switching HC forms overtime. The cost to benefit ratio justifies 
the implementation of this intervention.  Not only will it benefit the patient but also provide 
outstanding reviews and new clients to the clinic. This in return will provide added income to the 
clinic. 
Discussion of Results 
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 Unfortunately, due to the COVID-19 pandemic, implementation of this project was 
prohibited. Given the nature of the women’s health clinic, and the uncertainty of the virus course, 
the office manager made the decision to restrict visitors entering the clinic. Implementation was 
halted due to meeting and training dates being postponed until further notice. The projected 
results are that patients are monitored and assessed more closely during the first 3-12 months of 
the start of HC use. 
Implementing closer patient monitoring will elicit positive outcomes for not only the 
patient but for the clinic as well. With the use of CUDOS-D and patient surveys, the overall 
patient satisfaction scores are expected to increase. Patients will be given an opportunity to 
express how their treatment plan is going during each follow-up. Providing patients with 
opportunities for their voices to be heard and a say in the management of their care will in return 
improve adherence to treatment plans. The goal is to provide care that bridges the gap in 
depression related symptoms in women as a result of HC use. Lastly, an increase in patient 
satisfaction is expected to increase based on appreciation and concern for the patient’s well-
being on HC. As patient satisfaction increases, so will the referrals to the clinic, thus presenting 
an increase in revenue. 
Conclusions/Recommendations 
Studies suggest a correlation between hormonal contraception and the risk of 
psychological mood effects. However, with the implementation of patient monitoring and 
CUDOS-D questionnaire, the extent is decreased. It is clear from a research standpoint that there 
is a need for adequate management prior and throughout the course of hormonal therapy for 
those on these forms of treatment. As certified trained practitioners, it is our duty to provide safe 
and effective care. Through the implementation of HC monitoring, evidence has shown an 
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improvement if efficiency throughout the HC course, as well as patient management. By way of 
frequent follow-ups and assessments of mood changes during the initial first months of HC start, 
patients were more inclined to adhere to their regimen. With the added trust and security this 
monitoring has provided, patient satisfaction has increased, thus promoting the clinic in the long 
run. The end result is that there will be less women who develop signs and symptoms of 
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PICOT Question: In women currently taking hormonal contraceptives (P) how does individualized monitoring (I) compared to no 
monitoring (C) decrease the risk of hormonal contraceptive non-compliance related to depressive symptoms (O) over a 3 month 
period (T)? 
 
Evidence Synthesis Table 
Studies Design Sample Intervention Outcome 
 
A Randomized control 
trial 
n=224 COC- DMS 
PB-DMS 
 
COC use yielded increased rates of DMS 
 PB had lowest risk for DMS 
B Descriptive study n= 39 OC  PD occurrence 
 
OC use showed inc risk of PD occurrence 
C Systematic Review- 
Meta analysis 
n= 1000000 HC- dx of DMS HC showed positive correlation between HC use nd dx of D in 
adult years 
D Descriptive study n= 21 VR- SPBI 
NS w/ VR- SPBI 
NHC- SPBI 
VR showed risk of SPBI 
NS w/ VR showed increased rates of SPBI 
NHC yielded lower rates of SPBI when compared  
E Systematic review- 
Meta analysis 
n= 216 ICD-IA 
NICD- IA 
ICD training showed improved attitudes and compliance 
NICD decreased compliance with medication 
F Descriptive study n= 90 BCT w/ HC BCT yielded improvement with HC use 
G Literature review n= 46 CHC- DMS CHC use decreased positive mood 
H Cohort study n= 490 PMS- CHC use 
PMS- NCHC use 
Inc PMS symptoms with CHC use 
NCHC users yielded lower risk for PMS symptoms 
I Cross sectional study n= 815,662 HC- PDU PDU inc in NCHC users 
Decreased PDU in HC users 
J Descriptive study n= 1115 MDD-CUDOS-D Decreased symptoms of MDD with CUDOS-D use 
Legend: A = Bengtsdotter et al.,, B = Cheslack-Postava, Keyes, Lowe, & Koenen, C = McCall, Becca, & Rosenquist, D = Morotti et 
al., E = Ouyang, Peng, Botfied, & McGeechan, F = Phiri, King, & Newell, G = Shafrir, Worly & Gur, H = Yonker et al., I =  
Zettermark, Vicente & Merlo, J =Zimmerman, Harris, Martin & McGongial. BCT- Behavior change techniques, COC- Combined oral 
contraceptive, CUDOS-D- Clinically Useful Depression Screen, DMS- development of mood symptoms, HC- hormonal 
contraceptive, (n)ICD- (non)intrauterine contraceptive device, OC- Oral contraceptive, MDD- Major depressive disorder, NHC- non-
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hormonal contraceptive, NS- non-smoker, PB- placebo, PD- psychiatric disorder, PDU- psychotropic disorders, PMS- premenstrual 
syndrome, SPBI- self perceived body image, VR- vaginal ring. 
 
Outcomes Table: Effect of Hormonal Contraceptive on Depressive symptom Outcomes 
 A♦ B C♦ D♦ E♦ F G H I J♦ 
DMS ↑ ↑ ↑ ↑ ↓* NC ↓ ↑ ↑ ↓ 
PMS ↑ NC NC ↑ NC NC ↓ ↑ ↑ ↓* 
Adherence NC NE ↓ ↓* ↑ ↑ ↑ ↓ NE ↑* 
SM NE NE NE ↑* NE NE NE ↑ ↑* NE 
 
* = statistically significant findings 
♦ = higher level evidence 
 
Recommendations 
 Hormonal contraception (HC) use is highly prevalent among women, notably in women of reproductive ages and those who 
are pre or menopausal.  Due to ethical concerns, there is a decrease in the amount of controlled trials to help further and strengthen 
research regarding the association between HC and depression.  However, with the studies available, recommendations for practice 
remain achievable. Based on the synthesis table, articles recommendations for practice can be made.  
Predisposing factors such as current smoker,s drug user as well as previous  or current psychiatric disorders apart from depression 
must be assessed.  According to Morotti et., . and Zettermark, Vicente, & Merlo, smoking is associated with increased instances 
deprrssive mood symotoms as lowered adherence to medication.   Use of personalized patient monitoring or counseling with the 
prescribing provider and patient should be conducted to evaluate the pros and cons of a patient initiaing a HC regimen. By doing so, 
we help provide the patient with sufficient education and possible safer alternatives based on their needs. 
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 While the majority of studies displayed a total increase of depressive symptoms as it correlates with HC use, a couple studies 
showed an ulterior effect. Ouyang, Peng, Botfied, and McGeechan’s studies showed evidence of a lower risk of depressive symptoms 
in patients who received prior counseling before HC was initiated as well as continued monitoring throughout a specific duration of 
time during the HC use. For women with predisposing factors that increase their risk of exhibiting depressive symptoms, I recommend 
these women to be asses more frequently, instead of every 3 weeks, a weekly CUDOS-D survey will be sent via email or texted link 
weekly after the first 3 weeks. Also, I recommend that participants provide a seven-day journal. The journal should include current 
mood, and overall mood for the days prior to the survey, if any changes to behavior, energy level, and motivation have been noted.  
By providing this log, the provider is able to determine the best form of treatment based on the findings. 
 Lastly, due to the numerous forms of HC whether it is an oral pill or transdermal patch, it can be difficult to determine the best 
route for the patient. Having a hormonal contraception information binder that includes side effects, what they are best used to treat, 
maintainability, compatibility with certain comorbidities etc. should be available to use in practice. 
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In women currently taking hormonal contraceptives (P) how does individualized monitoring (I) compared to no monitoring (C) 
decrease the risk of hormonal contraceptive non-compliance related to depressive symptoms (O) over a 3 month period (T)? 
PICOT Question Type (Circle): Intervention   Etiology    Diagnosis or Diagnostic Test    Prognosis/Prediction   Meaning 
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Strength of the Evidence (i.e., level of evidence 























DV = ) 
What  scales were 
used to measure 
the outcome 
variables (e.g., 

















to be put 
into the 
table) 
Statistical findings or 
qualitative findings (i.e., 
for every statistical test 
you have in the data 
analysis column, you 
should have a finding) 
• Strengths and limitations  of the study 
• Risk or harm if study intervention or 
findings implemented 
• Feasibility of use in your practice  
• Remember: level of evidence (See Melnyk 
& Finout-Overholt, pp. 32-33) + quality of 
evidence = strength of evidence & confidence 
to act 























































































































































































57.8% -COC and 44.4%- 
placebo  
placebo, M difference 1.3 
(95% CI 0.3–2.3) 
DRSP scores-
placebo/COC M difference 







PD occurance-  
2.6% in past-year/ never 
OC users 
8.7% in former users 
FY- (OR=0.34; p<0.05) 
Strengths- 
• Double-blinded RCT 
• Included exclusion criteria 
• Tabled results 
 
Limitations-  
• Limited number of women 
• Subjects located through advertisement 
• Study inclusion date not clear 
 
Risk- There is risk for harm in implemetinging 
studies on psychological eefects of COC. 
Feasability- This study is feasible to cnduct in 
practice. 
Level of Evidence- Level II 





• Search criteria stated 
• Tabled results  
• Highlight of key findings 
• Included the exclusion criteria 
Limitations 
• Review was limited to English language  

































































































































































































































































































































































PY-  (p<0.05) OR of 0.37 
PY prevalence- PD, GAD, 





23,000 1st diagnosis 
HC users-2.2 (0.3) per 100 
person years 
Nonusers- 1.7 (0.28) per 







BW- (60.0±8.3; p1⁄40.050) 
BMI (22.1±3.1; p1⁄40.028) 
BDI- (7.7 ± 5.0 versus 5.8 






• Only one major database used 
• Information n consistency of OC use/timing 
 
 
There is risk associated with implementing this 
study. 
Feasibility- this study is not easily feasible and 
resources are not readily available 
Level of Evidence- I 




• Search criteria stated 
• Tabled results  
• Included the exclusion criteria 
• Large sample size. 
Limitations 
• Review was limited to English language  
• Study inclusion start date not clear 
• Possibility the subjects may 
have misunderstoonor incorrectly answered 
questions 
There is risk associated with implementing this 
study such as pt harm 
Feasability- this study is feasible 
and resurces are available 
Leve of Evidence- IV 







• Search criteria stated 
• Inclusion/exclusion criteria included 
• Data retrieval source 
Limitations 
• Study was limited to English 
• Data source conducted on small 
homegeneos group 
• Larger study needed. 
• Potential for under/over-reporting in 
questionnaries 
• Limited study population 
Riso of harm- Implementing this study is 
feasible in practice with little harm risk. 
Feasability- Feasable to recreate  
USPTSF Grade- B 






































































































































































































































































































































































FP- (70.4% vs. 9.9%) [16] 
NP-(12% vs. 66%)  
















EDU: I- 37 %;40 %; 42 % 
across arms                  
EDU: I-47 %,control 33 % 
INFO-baseline use 21.5 %, 
after intervention- 93.6 % 
Peers Info- I- 78 %, 
control- 59 %              
INFO FP:I- 20 %, control- 
14 %                           
INFO meeting: I- 23 %, 










HC containing less 






• Inclusion of Meta-analysis 
• Search criteria included 
• Summary of inclusion and exclusion criteria 
included 
• Low risk of bias due to high quality 
Limitations 
• Included only observational studies 
• Some confounders not controlled 
• Differences in study population, desing and 
analyzing methods 
Risk of harm: There are risks in implementing 
this study such as: Harm to pt 
Feasability: Feasable 
Level of Evidence: Level IV 






• Search criteria stated 
• Data extraction completed by 2 reviewers 
• Tabled results  
• Highlight of key findings 
• Included the exclusion criteria 
Limitations 
• Review was limited to English language  
• Study inclusion start date not clear 
• Restricted to RCT only 
• Small study sample 
 
Risk of Harm-There is risk associated with 
implementing this study. 
Feasibility- this study is feasible and resources 
are available 
Level of Evidence- I 






• Search criteria included 

































































































































































































































































































































































androgenic progestins have 
fewer adverse effects on 
mood. Continuous/non-
oral dosing of CHC has 
fewest mood effects; 
Women w/underlying MD- 











Screened Cohort: F(30, 
27000) = 0.35, p > 0.99, 
Randomized Cohort: F(30, 
14000) = 0.20, p > 0.99 
CHC use and symptom 
type -[F(10, 27000) = 3.12, 
p < 0.001] and the 
Randomized Cohort [F(10, 
14000) = 3.40, p < 0.001]. 
depressed, hopeless, or 
guilty ( p = 0.03); anger or 
irritability ( p = 0.002); 
diminished interest ( p = 
0.001); difficulty 
concentrating ( p = 0.03), 
feeling overwhelmed ( p = 
0.05), and physical 
symptoms ( p = 0.04)  
 
Adolescent- 1st time 
psychotropic drugs of 1.34 
(95% CI: 1.30–1.37)                              
association w/ psychtropic 
drug use-non-oral 
progesterone-only OR 4.47 
(95% CI: 2.08–8.78) COC 
users had an OR of 1.52 
(95% CI: 1.41–1.64)  
• Heterogenous studies 
• Summary of inclusion and exclusion criteria 
included 
Limitations 
• Study inclusion dates range begin in late 
1980s 
• Incosistencies in methodology 
• Differences in study population, desing and 
analyzing methods 
 
Risk of harm: There are no risks in 
implementing this study  
Feasability: Feasable 
Level of Evidence: Level IV 





• Search criteria stated 
• Tabled results  
• Included the exclusion criteria 
Limitations 
• Review was limited to English language  
• Study inclusion start date not clear 
Risk of Harm-There is no risk associated with 
implementing this study such as pt harm 
Feasability- this study is feasible and resurces 
are available 
Leve of Evidence- IV 











• Search criteria stated 
• Large sample size 
• Tabled results  
• Included the exclusion criteria 
Limitations 
• Lack of accurate measurement 
• Small sample size 
There is risk associated with implementing this 




Drug Use in 
Adolescent 
Girls but not 











































































































CI, z, M, P 
Adult- DMPA inj- OR of 
1.56 (95% CI: 1.34–1.82).  
IUD- OR of 2.90 (95% CI: 
2.22–3.79)  
 
Study size- 1,115.  M= 
102.7 sec to complete 
CUDOS-D. 40% vs. 14% 
prefer use in tmt plan. Z= 
2.31, p. 05 
study such as pt harm 
Feasability- this study is feasible and resurces 
are available 
Leve of Evidence- IV 






• Search criteria stated 
• Inclusion criteria specidfied 
• Tabled results 
• Stated exclusion critiria  
• Test-retest reliability performed 
Limitations 
• Test-retest not performed on all study 
patients. 
• Trained diagnoster not used for on all 
patients. 
Feasability- This study is feasible and able to be 
replicated. 
Level of Evidence- Level IV 
USPSTF- B 
Legend: 
COC- combined oral conrceptive 
MINI- Mini Interatioal Neuropsychiatric Interview 
DRSP- Daily Record of Severity of Problems 
CHC- Cyclic Hormonal Contraception 
RD-Recreational Drug 
VR- Vaginal Ring 
SFRS- Stunkard Figure Rating Scale 
BDI- Beck’s Depression Inventory Questionnare  
MFSQ- McCoy Female Sexuality Questionnare 
PC- Pearson’s Correlation 
PD- Panic disorder 
HC- Hormonal contraception 
BCT- Behaviral Change Techniques  
 
M- Median 
NPA- No physican advice 
OC- Oral Contraceptive 
OR- Odds Ratio 
P- Precentage 
PAA- Physcian advice against  
PE- Pulmonary embolism 
POP- Progestin only 
RR – Risk Ratio 
R- Range  
 
CONTRACEPTIVE MONITORING                                                                                           30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
